Abeona Therapeutics Inc (ABEO) - Total Liabilities
Based on the latest financial reports, Abeona Therapeutics Inc (ABEO) has total liabilities worth $51.45 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check ABEO cash and liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Abeona Therapeutics Inc - Total Liabilities Trend (1995–2025)
This chart illustrates how Abeona Therapeutics Inc's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see ABEO total asset value.
Abeona Therapeutics Inc Competitors by Total Liabilities
The table below lists competitors of Abeona Therapeutics Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Rishabh Instruments Limited
NSE:RISHABH
|
India | Rs2.67 Billion |
|
Channel Well Technology Co Ltd
TWO:3078
|
Taiwan | NT$2.90 Billion |
|
Eyepoint Pharmaceuticals Inc
NASDAQ:EYPT
|
USA | $51.51 Million |
|
Orizon Valorização de Resíduos S.A
SA:ORVR3
|
Brazil | R$2.69 Billion |
|
Taiwan Taxi Co Ltd
TWO:2640
|
Taiwan | NT$1.92 Billion |
|
CapsoVision, Inc. Common Stock
NASDAQ:CV
|
USA | $5.40 Million |
|
JinGuan Electric Co Ltd
SHG:688517
|
China | CN¥511.86 Million |
|
Putnam Premier Income Trust
NYSE:PPT
|
USA | $213.25 Million |
Liability Composition Analysis (1995–2025)
This chart breaks down Abeona Therapeutics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See how leveraged is Abeona Therapeutics Inc's balance sheet to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 6.63 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.40 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.29 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Abeona Therapeutics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Abeona Therapeutics Inc (1995–2025)
The table below shows the annual total liabilities of Abeona Therapeutics Inc from 1995 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $60.35 Million | -7.00% |
| 2024-12-31 | $64.90 Million | +31.97% |
| 2023-12-31 | $49.18 Million | +31.30% |
| 2022-12-31 | $37.45 Million | +0.63% |
| 2021-12-31 | $37.22 Million | -23.49% |
| 2020-12-31 | $48.65 Million | +8.22% |
| 2019-12-31 | $44.95 Million | +11.39% |
| 2018-12-31 | $40.35 Million | +365.55% |
| 2017-12-31 | $8.67 Million | -27.53% |
| 2016-12-31 | $11.96 Million | -3.03% |
| 2015-12-31 | $12.33 Million | +4.83% |
| 2014-12-31 | $11.77 Million | -23.56% |
| 2013-12-31 | $15.39 Million | -18.15% |
| 2012-12-31 | $18.81 Million | -12.08% |
| 2011-12-31 | $21.39 Million | -27.65% |
| 2010-12-31 | $29.57 Million | +3.48% |
| 2009-12-31 | $28.57 Million | +86.05% |
| 2008-12-31 | $15.36 Million | +81.35% |
| 2007-12-31 | $8.47 Million | -48.09% |
| 2006-12-31 | $16.31 Million | +42.47% |
| 2005-12-31 | $11.45 Million | -35.50% |
| 2004-12-31 | $17.75 Million | +0.65% |
| 2003-12-31 | $17.64 Million | -7.17% |
| 2002-12-31 | $19.00 Million | +15.78% |
| 2001-12-31 | $16.41 Million | +5.71% |
| 2000-12-31 | $15.52 Million | +1452.20% |
| 1999-12-31 | $1.00 Million | +66.67% |
| 1998-12-31 | $600.00K | -29.25% |
| 1997-12-31 | $848.00K | -2.30% |
| 1996-12-31 | $868.00K | +95.94% |
| 1995-12-31 | $443.00K | -- |
About Abeona Therapeutics Inc
Abeona Therapeutics Inc., a commercial-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases in the United States. It develops ZEVASKYN, an autologous, cell-based gene therapy for the treatment of patients with recessive dystrophic epidermolysis bullosa. The company also develops ABO-503 to treat X-linked retinoschisis; ABO-504 for the treatment of starga… Read more